TELO vs. OGI, VERU, ZVRA, IVA, ACRV, ATOS, GALT, OMER, PBYI, and CAPR
Should you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Organigram (OGI), Veru (VERU), Zevra Therapeutics (ZVRA), Inventiva (IVA), Acrivon Therapeutics (ACRV), Atossa Therapeutics (ATOS), Galectin Therapeutics (GALT), Omeros (OMER), Puma Biotechnology (PBYI), and Capricor Therapeutics (CAPR). These companies are all part of the "pharmaceutical preparations" industry.
Telomir Pharmaceuticals (NASDAQ:TELO) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
34.6% of Organigram shares are owned by institutional investors. 0.1% of Organigram shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Telomir Pharmaceuticals has a net margin of 0.00% compared to Organigram's net margin of -188.38%. Telomir Pharmaceuticals' return on equity of 0.00% beat Organigram's return on equity.
Organigram received 197 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.
In the previous week, Telomir Pharmaceuticals and Telomir Pharmaceuticals both had 3 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 1.25 equaled Organigram'saverage media sentiment score.
Telomir Pharmaceuticals has higher earnings, but lower revenue than Organigram.
Summary
Organigram beats Telomir Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telomir Pharmaceuticals Competitors List
Related Companies and Tools
